Morrison Briggs's Form 4 filing
Syndax Pharmaceuticals IncSNDX · filed Sep 21, 2022
- Accession no.
- 0001562180-22-006788
- Filed
- Sep 21, 2022
- Trade date
- Sep 19-20, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $4.02M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Morrison BriggsCIK 0001654430 | Director, Officer (President, Head of R&D) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 19, 2022 | Common Stock | MOption exerciseAcquired | +114,339 | $10.90 | +$1,246,295.1 | 132,175 | Direct | |
| Sep 19, 2022 | Common Stock | SSaleDisposed | −114,339 | $23.03F2 | −$2,633,227.17 | 17,836 | Direct | |
| Sep 20, 2022 | Common Stock | MOption exerciseAcquired | +59,649 | $10.90 | +$650,174.1 | 77,485 | Direct | |
| Sep 20, 2022 | Common Stock | SSaleDisposed | −59,649 | $23.25F3 | −$1,386,839.25 | 17,836 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 19, 2022 | Common Stock | MOption exerciseDisposed | −114,339 | $0.00 | $0 | 0 | Direct | |
| Sep 20, 2022 | Common Stock | MOption exerciseDisposed | −59,649 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sale prices ranged from $22.50 to $23.35
Referenced by the price of 1 transaction in Table I.
- F3
The sale prices ranged from $22.60 to $23.75
Referenced by the price of 1 transaction in Table I.